Skip to main content

Clinical trial Brightline-1

A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma (Brightline-1 ; 1403-0008)

Organ sarcome
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 2/3
Academic trial Non
Sponsor Boehringer Ingelheim
EudraCT Identifier 2021-002392-20
Last update